CTOs on the Move

Fidelity and Health Int'l Co. Lt

www.fidelity-and-health.com

 
Fidelity and Health Int'l Co. Lt is a Pasadena, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Programable Devices Inc

Programable Devices Inc is a Danvers, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cerexa

Cerexa is a Oakland, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Physician Health Partners

Physician Health Partners is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hospice of Michigan

With roots dating back to the 1970s, we are the most experienced provider of hospice care in Michigan. Currently serving more than 1,700 patients daily, in 56 counties, we`re also the largest in our state, and among the largest recognized 501c3 non-profit advanced illness management organizations in the nation. We provide care for all—regardless of age, diagnosis, or ability to pay. Last year, our commitment extended $4 million beyond what was reimbursed by insurance. Because we welcome those who are uninsured, or whose treatment is more expensive than what other hospices can provide, we depend on the financial support of our donors for the treatments, medications, services, grief support, and spiritual care of patients and families in need.

Kite Pharma

Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.